Optimata recently became a partner in the new MELanoma disease comPLEXity (MEL-PLEX) research program, aimed at applying translational cancer systems biology and cancer systems medicine to study novel treatment options for personalized, patient-tailored melanoma therapies. The MEL-PLEX consortium is composed of 15 groups from 11 countries, including European and international academic/clinical (10) and private sector (8) leaders, to investigate the network-level and multi-scale regulation of disease-relevant signaling in melanoma, personalized melanoma therapy, melanoma systems biology and cancer systems medicine. MEL-PLEX aims to (i) achieve an unmatched depth of molecular and mechanistic disease understanding, (ii) exploit this knowledge to develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iii) provide superior and clinically relevant tools and biomarker signatures for personalizing and optimizing melanoma therapy. The project is supported by the European HORIZON 2020 - MSCA-ITN-2014-ETN: Marie Skłodowska-Curie Innovative Training Networks (ITN-ETN); contract # 642295.